SPC now also warns that vemurafenib may increase the plasma exposure of drugs that are P-gp substrates, therefore caution should be exercised, and dose reduction and/or additional drug level monitoring for P-gp substrates with narrow therapeutic index (e.g. digoxin, dabigatran etexilate, aliskiren) may be considered if these drugs are used concomitantly with vemurafenib.